MDS Europe - Università Degli Studi di Pavia

Università Degli Studi di Pavia

The University of Pavia & Fondazione IRCCS Policlinico S. Matteo is a centre of excellence for biomedical basic, translational and clinical research. The Department of Molecular Medicine of the University of Pavia and the Department of Hematology Oncology Fondazione IRCCS Policlinico S. Matteo are a reference centre for the diagnosis and treatment of myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and other myeloid neoplasms. The Departments combine in a single body an In-Patient Ward, a Stem-Cell Transplantation Center, an Out-Patient Unit, diagnostic and research laboratories, and a Data Center. Diagnostic and research laboratories consist in molecular biology and sequencing, cytogenetics and molecular genetics, flow cytometry and immunobiology, hematopoietic stem cell manipulation. The department is currently following more than 500 patients with myeloid neoplasms and about 150 patients with MDS or MDS/MPN are referred to the unit each year. The Pavia research group has made a significant contribution to understanding the molecular basis of myeloid neoplasms, including the identification of recurrent somatically acquired mutations in SF3B1, a gene encoding a component of the RNA splicing machinery, in patients with MDS and ring sideroblasts, and of JAK2 and CALR mutations in myeloproliferative neoplasms and MDS/MPN. The group made significant contribution to the prognostic assessment, including the prognostic value of transfusion dependence and bone marrow fibrosis and the development of dynamic prognostic scoring system, and to the development of diagnostic and therapeutic guidelines for these disorders.

Our team

Prof. Luca Malcovati, MD

Luca is Associate Professor of Hematology at the University of Pavia Medical School and with special interest and expertise in myeloid neoplasms, in particular myelodysplastic and myelodysplastic/myeloproliferative neoplasms. Research activities of the group of Luca Malcovati made a significant contribution to understanding the molecular basis of myeloid neoplasms and to the integration of somatic mutations in the clinical management of patients. These contributions included the identification of recurrent somatically acquired mutations in splicing factors, and the elucidation of the clinical and prognostic implications of driver mutations in these disorders. Luca is a member of the Steering Committee of the EUMDS Registry, of the International Working Group for prognosis of MDS, of the Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the WHO Classification of Haematopoietic and Lymphoid Tumours Clinical Advisory Committee. Luca will coordinate all tasks in WP4, which focusses on outcome prediction. In WP5 he will also contribute to the development of evidence-based guidelines in a web-based environment.

Chiara Elena, MD

Chiara is consultant haematologist at the Department of Haematology, Fondazione IRCCS Policlinico S. Matteo Matteo & University of Pavia, Pavia, Italy. Dr. Elena’s research activity has mainly dealt with the clinical and molecular characterization of myeloid neoplasms, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). She is active in clinical and translational research programs in MDS and MDS/MPN.

Elisa Bono, MD

Elisa is a haematologist, attending physician at the Department of Haematology, Fondazione IRCCS Policlinico S. Matteo & University of Pavia, Pavia, Italy. Her research activity has mainly dealt with the clinical and molecular characterization of myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). She is currently active in clinical and translational research programs in MDS and MDS/MPN.

Gabriele Todisco, MD

Gabriele is a haematologist, attending physician at the Department of Haematology, Fondazione IRCCS Policlinico S. Matteo & University of Pavia, Pavia, Italy. His research activity has mainly dealt with the clinical and molecular characterization of myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). He is currently active in clinical and translational research programs in MDS and MDS/MPN.

Anna Gallì

Anna obtained her degree in Biological Sciences in 2000, at the University of Pavia, Pavia, Italy, and PhD in Pharmacology in 2005. Her research activity has been focused on iron metabolism and related disorders, and on genomic analysis of hematopoietic stem cell in patients with myelodysplastic syndromes (MDS). Current research interests are mainly focused on the identification of acquired mutations in through next generation sequencing in MDS and related myeloid disorders.

Elisabetta Molteni, PhD

Elisabetta obtained her Master Degree in Medical and Pharmaceutical Biotechnology, and PhD in Biomolecular Sciences and Biotechnology, at the University of Pavia, Italy. She is currently Research Fellow at University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia. Her current research interests and core activities mainly concern molecular and cellular biology, and genome analysis by next generation sequencing.

Virginia Valeri Ferretti, PhD

Virginia graduated in Biostatistics and Experimental Statistic and she obtained her PhD in Public Health and Education at the University of Pavia, Italy. Currently, she is research associate at the Department of Molecular Medicine, University of Pavia. Her activity is mainly focussed on statistical inference of clinical and molecular data of patients with haematological malignancies, including myeloid neoplasms.

Sara Pozzi

Sara obtained her degree in Biological Sciences in 2017, at the University of Pavia, Pavia, Italy. Current research interests are mainly focused on the integration of clinical and molecular data in MDS and related myeloid disorders.

Login